Inspire Investing LLC Reduces Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Inspire Investing LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,791 shares of the medical research company’s stock after selling 904 shares during the quarter. Inspire Investing LLC’s holdings in IQVIA were worth $3,496,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of IQV. Capital Performance Advisors LLP purchased a new position in IQVIA in the third quarter valued at $27,000. Park Place Capital Corp purchased a new position in IQVIA in the third quarter valued at $28,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. boosted its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on IQV. TD Cowen decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Evercore ISI decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Truist Financial lowered their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Price Performance

Shares of IQV opened at $205.37 on Thursday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock’s 50 day moving average is $199.41 and its two-hundred day moving average is $221.19. The firm has a market capitalization of $37.27 billion, a PE ratio of 26.95, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.